Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (phase lb):~* Females with Breast cancer that is histologically or cytologically confirmed, HER2 negative and locally advanced or metastatic as confirmed by radiology~* ECOG performance status 0 and 1~* Adequate bone marrow and organ function~Exclusion Criteria (Phase lb):~* Previous treatment with PI3K and/or mTOR inhibitors~* Symptomatic Central Nervous System (CNS) metastases~* Concurrent malignancy or malignancy in the last 5 years prior to start of study treatment~* Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study drug~* Active cardiac disease (e.g. LVEF less than institutional lower limit of normal, QTcF \> 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)~* Inadequately controlled hypertension~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 and/or paclitaxel~* Treatment at start of study treatment with drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of isoenzyme CYP3A4, warfarin and coumadin analogues, LHRH agonists~* Sensitivity to paclitaxel treatment~* Uncontrolled diabetes mellitus~* Pregnant or nursing (lactating) woman~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BEZ235 100 mg bid + paclitaxel 80 mg (phase lb) (Type: EXPERIMENTAL): Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
- BEZ235 200 mg bid + paclitaxel 80 mg (phase lb) (Type: EXPERIMENTAL): Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).